Overview
- A federal securities class action covers purchasers of Cytokinetics common stock from December 27, 2023 through May 6, 2025.
- Investor-rights firms Faruqi & Faruqi, Glancy Prongay & Murray, and the Rosen Law Firm issued new notices urging filings for lead-plaintiff status by November 17, 2025.
- The complaint alleges executives promoted a September 26, 2025 PDUFA date and projected second-half 2025 approval without disclosing REMS-related risk.
- Plaintiffs cite a May 6, 2025 call stating the NDA was filed without a REMS despite pre-NDA FDA safety discussions, with a later REMS submission alleged to have added roughly three months.
- No class has been certified, and investors may choose to join the case, seek counsel, or remain absent as the litigation continues in federal court.